-
1
-
-
4644354309
-
Hepatitis B vaccines: WHO position paper
-
World Health Organization
-
World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol. Rec. 79, 255-263 (2004).
-
(2004)
Wkly Epidemiol. Rec
, vol.79
, pp. 255-263
-
-
-
2
-
-
58749111990
-
-
Sorrell MF, Belongia EA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann. Intern. Med. 150 (2), 104-110 (2009).
-
Sorrell MF, Belongia EA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann. Intern. Med. 150 (2), 104-110 (2009).
-
-
-
-
3
-
-
33646413672
-
The global health burden of infection-associated cancers in the year 2002
-
Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118 (12), 3030-3044 (2006).
-
(2006)
Int. J. Cancer
, vol.118
, Issue.12
, pp. 3030-3044
-
-
Parkin, D.M.1
-
4
-
-
1642410856
-
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
-
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 11 (2), 97-107 (2004).
-
(2004)
J. Viral Hepat
, vol.11
, Issue.2
, pp. 97-107
-
-
Lavanchy, D.1
-
5
-
-
33644858331
-
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
-
Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (3), 678-686 (2006).
-
(2006)
Gastroenterology
, vol.130
, Issue.3
, pp. 678-686
-
-
Iloeje, U.H.1
Yang, H.I.2
Su, J.3
Jen, C.L.4
You, S.L.5
Chen, C.J.6
-
6
-
-
33746675024
-
Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study
-
Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol. 101 (8), 1797-1803 (2006).
-
(2006)
Am. J. Gastroenterol
, vol.101
, Issue.8
, pp. 1797-1803
-
-
Chen, G.1
Lin, W.2
Shen, F.3
Iloeje, U.H.4
London, W.T.5
Evans, A.A.6
-
7
-
-
29944436855
-
-
Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (1), 65-73 (2006). •• Prospective cohort study of untreated HBV-infected individuals with over 11 years of follow-up that described a linear relationship between increasing serum HBV DNA and the development of hepatocellular carcinoma (HCC), demonstrating that the degree of viremia predicts HCC risk, independent of cirrhosis, hepatitis B e antigen (HBeAg) seropositivity, or alanine aminotransferase levels.
-
Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (1), 65-73 (2006). •• Prospective cohort study of untreated HBV-infected individuals with over 11 years of follow-up that described a linear relationship between increasing serum HBV DNA and the development of hepatocellular carcinoma (HCC), demonstrating that the degree of viremia predicts HCC risk, independent of cirrhosis, hepatitis B e antigen (HBeAg) seropositivity, or alanine aminotransferase levels.
-
-
-
-
8
-
-
51049117284
-
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma
-
Yang HI, Yeh SH, Chen PJ et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl Cancer Inst. 100 (16), 1134-1143 (2008).
-
(2008)
J. Natl Cancer Inst
, vol.100
, Issue.16
, pp. 1134-1143
-
-
Yang, H.I.1
Yeh, S.H.2
Chen, P.J.3
-
9
-
-
38349094747
-
High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma
-
Chan HL, Tse CH, Mo F et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J. Clin. Oncol. 26 (2), 177-182 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, Issue.2
, pp. 177-182
-
-
Chan, H.L.1
Tse, C.H.2
Mo, F.3
-
10
-
-
19544391413
-
-
Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351 (15), 1521-1531 (2004). •• Prospective multicenter, randomized, double-blind, placebo-controlled trial in which patients with advanced fibrosis who were randomized to receive antiviral therapy with lamivudine had a lower incidence of HCC or disease progression within 3 years of follow-up.
-
Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351 (15), 1521-1531 (2004). •• Prospective multicenter, randomized, double-blind, placebo-controlled trial in which patients with advanced fibrosis who were randomized to receive antiviral therapy with lamivudine had a lower incidence of HCC or disease progression within 3 years of follow-up.
-
-
-
-
11
-
-
33847701354
-
Chronic hepatitis B
-
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 45 (2), 507-539 (2007).
-
(2007)
Hepatology
, vol.45
, Issue.2
, pp. 507-539
-
-
Lok, A.S.1
McMahon, B.J.2
-
12
-
-
57149091722
-
-
Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 6 (12), 1315-1341 (2008). • Comprehensive treatment algorithm developed by an international expert panel outlining treatment strategies for chronic hepatitis B based on current evidence, including selection of treatment candidates and recommended antiviral agents, on-treatment monitoring and management of antiviral resistance.
-
Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 6 (12), 1315-1341 (2008). • Comprehensive treatment algorithm developed by an international expert panel outlining treatment strategies for chronic hepatitis B based on current evidence, including selection of treatment candidates and recommended antiviral agents, on-treatment monitoring and management of antiviral resistance.
-
-
-
-
13
-
-
58149296156
-
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
-
European Association for the Study of the Liver
-
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 50 (2), 227-242 (2009).
-
(2009)
J. Hepatol
, vol.50
, Issue.2
, pp. 227-242
-
-
-
14
-
-
33644506166
-
Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005
-
Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43 (2 Suppl. 1), S173-S181 (2006).
-
(2006)
Hepatology
, vol.43
, Issue.2 SUPPL. 1
-
-
Yim, H.J.1
Lok, A.S.2
-
15
-
-
27444441182
-
Prognostic determinants for chronic hepatitis B in Asians: Therapeutic implications
-
Yuen MF, Yuan HJ, Wong DK et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54 (11), 1610-1614 (2005).
-
(2005)
Gut
, vol.54
, Issue.11
, pp. 1610-1614
-
-
Yuen, M.F.1
Yuan, H.J.2
Wong, D.K.3
-
16
-
-
34247222010
-
Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B
-
Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132 (4), 1574-1585 (2007).
-
(2007)
Gastroenterology
, vol.132
, Issue.4
, pp. 1574-1585
-
-
Ghany, M.1
Liang, T.J.2
-
17
-
-
4644298430
-
Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B
-
Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J. Viral Hepat. 11 (5), 432-438 (2004).
-
(2004)
J. Viral Hepat
, vol.11
, Issue.5
, pp. 432-438
-
-
Fung, S.K.1
Wong, F.2
Hussain, M.3
Lok, A.S.4
-
18
-
-
58149316191
-
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy
-
Shouval D, Lai CL, Chang TT et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy J. Hepatol. 50 (2), 289-295 (2009).
-
(2009)
J. Hepatol
, vol.50
, Issue.2
, pp. 289-295
-
-
Shouval, D.1
Lai, C.L.2
Chang, T.T.3
-
19
-
-
54849146600
-
Hepatitis B virus infection
-
Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med. 359 (14), 1486-1500 (2008).
-
(2008)
N. Engl. J. Med
, vol.359
, Issue.14
, pp. 1486-1500
-
-
Dienstag, J.L.1
-
20
-
-
73949132784
-
-
entecavir, Bristol-Meyers Squibb Company, Princeton, NJ, USA, January
-
Baraclude® (entecavir). Bristol-Meyers Squibb Company, Princeton, NJ, USA. Product information, revised January 2009.
-
(2009)
Product information, revised
-
-
Baraclude®1
-
21
-
-
0030872946
-
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
-
Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41 (7), 1444-1448 (1997).
-
(1997)
Antimicrob. Agents Chemother
, vol.41
, Issue.7
, pp. 1444-1448
-
-
Innaimo, S.F.1
Seifer, M.2
Bisacchi, G.S.3
Standring, D.N.4
Zahler, R.5
Colonno, R.J.6
-
22
-
-
0032907705
-
Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
-
Yamanaka G, Wilson T, Innaimo S et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother. 43 (1), 190-193 (1999).
-
(1999)
Antimicrob. Agents Chemother
, vol.43
, Issue.1
, pp. 190-193
-
-
Yamanaka, G.1
Wilson, T.2
Innaimo, S.3
-
23
-
-
0031761652
-
In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir
-
Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. 42 (12), 3200-3208 (1998).
-
(1998)
Antimicrob. Agents Chemother
, vol.42
, Issue.12
, pp. 3200-3208
-
-
Seifer, M.1
Hamatake, R.K.2
Colonno, R.J.3
Standring, D.N.4
-
24
-
-
34247107229
-
Inhibition of hepatitis B virus polymerase by entecavir
-
Langley DR, Walsh AW, Baldick CJ et al. Inhibition of hepatitis B virus polymerase by entecavir. J. Virol. 81 (8), 3992-4001 (2007).
-
(2007)
J. Virol
, vol.81
, Issue.8
, pp. 3992-4001
-
-
Langley, D.R.1
Walsh, A.W.2
Baldick, C.J.3
-
25
-
-
0035114188
-
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
-
Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 107 (4), 449-455 (2001).
-
(2001)
J. Clin. Invest
, vol.107
, Issue.4
, pp. 449-455
-
-
Ono, S.K.1
Kato, N.2
Shiratori, Y.3
-
26
-
-
0035991863
-
Efficacies of entecavir against lamivudineresistant hepatitis B virus replication and recombinant polymerases in vitro
-
Levine S, Hernandez D, Yamanaka G et al. Efficacies of entecavir against lamivudineresistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. 46 (8), 2525-2532 (2002).
-
(2002)
Antimicrob. Agents Chemother
, vol.46
, Issue.8
, pp. 2525-2532
-
-
Levine, S.1
Hernandez, D.2
Yamanaka, G.3
-
27
-
-
26844500312
-
A dose-ranging study of the effcacy and tolerability of entecavir in lamivudinerefractory chronic hepatitis B patients
-
Chang TT, Gish RG, Hadziyannis SJ et al. A dose-ranging study of the effcacy and tolerability of entecavir in lamivudinerefractory chronic hepatitis B patients. Gastroenterology 129 (4), 1198-1209 (2005).
-
(2005)
Gastroenterology
, vol.129
, Issue.4
, pp. 1198-1209
-
-
Chang, T.T.1
Gish, R.G.2
Hadziyannis, S.J.3
-
28
-
-
0035991456
-
Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B
-
Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J. Hepatol. 37 (1), 137-144 (2002).
-
(2002)
J. Hepatol
, vol.37
, Issue.1
, pp. 137-144
-
-
Wolters, L.M.1
Hansen, B.E.2
Niesters, H.G.3
DeHertogh, D.4
de Man, R.A.5
-
29
-
-
58949087420
-
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir
-
Leung N, Peng CY, Hann HW et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 49 (1), 72-79 (2009).
-
(2009)
Hepatology
, vol.49
, Issue.1
, pp. 72-79
-
-
Leung, N.1
Peng, C.Y.2
Hann, H.W.3
-
30
-
-
33644818518
-
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
-
Prospective, randomized, double-blind clinical trial that demonstrated greater viral suppression, biochemical response and histologic improvement in HBeAgpositive patients who received entecavir in comparison with lamivudine, •
-
Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354 (10), 1001-1010 (2006). • Prospective, randomized, double-blind clinical trial that demonstrated greater viral suppression, biochemical response and histologic improvement in HBeAgpositive patients who received entecavir in comparison with lamivudine.
-
(2006)
N. Engl. J. Med
, vol.354
, Issue.10
, pp. 1001-1010
-
-
Chang, T.T.1
Gish, R.G.2
de Man, R.3
-
31
-
-
35649020315
-
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B
-
Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133 (5), 1437-1444 (2007).
-
(2007)
Gastroenterology
, vol.133
, Issue.5
, pp. 1437-1444
-
-
Gish, R.G.1
Lok, A.S.2
Chang, T.T.3
-
32
-
-
70350037583
-
Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B
-
Epub ahead of print
-
Chang TT, Chao YC, Gorbakov VV et al. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J. Viral Hepat. (2009) (Epub ahead of print).
-
(2009)
J. Viral Hepat
-
-
Chang, T.T.1
Chao, Y.C.2
Gorbakov, V.V.3
-
33
-
-
73949091802
-
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B
-
Epub ahead of print
-
Gish RG, Chang TT, Lai CL et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J. Viral Hepat. (2009) (Epub ahead of print).
-
(2009)
J. Viral Hepat
-
-
Gish, R.G.1
Chang, T.T.2
Lai, C.L.3
-
34
-
-
58649118949
-
Five years of continuous entecavir for nucleoside-naive HBeAg+ chronic hepatitis B: Results from study ETV-901 [abstract]
-
Han SH, Chang TT, Chao YC et al. Five years of continuous entecavir for nucleoside-naive HBeAg+ chronic hepatitis B: results from study ETV-901 [abstract]. Hepatology 48 (S1), 705A-706A (2008).
-
(2008)
Hepatology
, vol.48
, Issue.S1
-
-
Han, S.H.1
Chang, T.T.2
Chao, Y.C.3
-
35
-
-
33644822860
-
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
-
Prospective, randomized, double-blind clinical trial that demonstrated greater viral suppression, biochemical response and histologic improvement in HBeAgnegative patients who received entecavir in comparison with lamivudine, •
-
Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354 (10), 1011-1020 (2006). • Prospective, randomized, double-blind clinical trial that demonstrated greater viral suppression, biochemical response and histologic improvement in HBeAgnegative patients who received entecavir in comparison with lamivudine.
-
(2006)
N. Engl. J. Med
, vol.354
, Issue.10
, pp. 1011-1020
-
-
Lai, C.L.1
Shouval, D.2
Lok, A.S.3
-
36
-
-
33744531146
-
Entecavir for treatment of lamivudinerefractory, HBeAg-positive chronic hepatitis B
-
Sherman M, Yurdaydin C, Sollano J et al. Entecavir for treatment of lamivudinerefractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130 (7), 2039-2049 (2006).
-
(2006)
Gastroenterology
, vol.130
, Issue.7
, pp. 2039-2049
-
-
Sherman, M.1
Yurdaydin, C.2
Sollano, J.3
-
37
-
-
47149108478
-
Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks
-
Sherman M, Yurdaydin C, Simsek H et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 48 (1), 99-108 (2008).
-
(2008)
Hepatology
, vol.48
, Issue.1
, pp. 99-108
-
-
Sherman, M.1
Yurdaydin, C.2
Simsek, H.3
-
38
-
-
66149115173
-
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy
-
Summary of long-term resistance development in patients treated with entecavir for chronic HBV infection based on comprehensive resistance monitoring of cohorts treated in prospective studies with at least 5 years of follow-up, •
-
Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49 (5), 1503-1514 (2009). • Summary of long-term resistance development in patients treated with entecavir for chronic HBV infection based on comprehensive resistance monitoring of cohorts treated in prospective studies with at least 5 years of follow-up.
-
(2009)
Hepatology
, vol.49
, Issue.5
, pp. 1503-1514
-
-
Tenney, D.J.1
Rose, R.E.2
Baldick, C.J.3
-
39
-
-
70350133508
-
Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients [abstract]
-
S
-
Tenney DJ, Pokornowski KA, Rose RE et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients [abstract]. J. Hepatol. 50 (Suppl. 1), S10 (2009).
-
(2009)
J. Hepatol
, vol.50
, Issue.SUPPL. 1
, pp. 10
-
-
Tenney, D.J.1
Pokornowski, K.A.2
Rose, R.E.3
-
40
-
-
66149164719
-
Antiviral resistance and hepatitis B therapy
-
Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 49 (Suppl. 5), S174-S184 (2009).
-
(2009)
Hepatology
, vol.49
, Issue.SUPPL. 5
-
-
Ghany, M.G.1
Doo, E.C.2
-
41
-
-
73949119385
-
Long-term histologic improvement with entecavir (ETV) therapy in patients with chronic hepatitis B (CHB) from Japanese and worldwide development programs [abstract]
-
Liaw YF, Chang TT, Wu SS et al. Long-term histologic improvement with entecavir (ETV) therapy in patients with chronic hepatitis B (CHB) from Japanese and worldwide development programs [abstract]. Gastroenterology 136 (5, Suppl. 1), A798-A799 (2009).
-
(2009)
Gastroenterology
, vol.136
, Issue.5 and SUPPL. 1
-
-
Liaw, Y.F.1
Chang, T.T.2
Wu, S.S.3
-
42
-
-
73949122888
-
Regression of fbrosis/cirrhosis with long-term entecavir therapy in chronic hepatitis B (CHB) patients with baseline bridging fibrosis or cirrhosis: Results from studies ETV-022,-027 and-901 [abstract]
-
Schiff ER, Lee SS, Chao YC et al. Regression of fbrosis/cirrhosis with long-term entecavir therapy in chronic hepatitis B (CHB) patients with baseline bridging fibrosis or cirrhosis: results from studies ETV-022,-027 and-901 [abstract]. Gastroenterology 136 (5 Suppl. 1), A866 (2009).
-
(2009)
Gastroenterology
, vol.136
, Issue.5 SUPPL. 1
-
-
Schiff, E.R.1
Lee, S.S.2
Chao, Y.C.3
-
43
-
-
55349135866
-
Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis
-
Schiff E, Simsek H, Lee WM et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am. J. Gastroenterol. 103 (11), 2776-2783 (2008).
-
(2008)
Am. J. Gastroenterol
, vol.103
, Issue.11
, pp. 2776-2783
-
-
Schiff, E.1
Simsek, H.2
Lee, W.M.3
-
44
-
-
66149190942
-
Side effects of long-term oral antiviral therapy for hepatitis B
-
Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49 (5, Suppl.), S185-S195 (2009).
-
(2009)
Hepatology
, vol.49
, Issue.5 and SUPPL.
-
-
Fontana, R.J.1
-
45
-
-
24344478565
-
Molecular virology and the development of resistant mutants: Implications for therapy
-
Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin. Liver Dis. 25 (Suppl. 1), 9-19 (2005).
-
(2005)
Semin. Liver Dis
, vol.25
, Issue.SUPPL. 1
, pp. 9-19
-
-
Locarnini, S.1
-
46
-
-
10744225554
-
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
-
Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (6), 1714-1722 (2003).
-
(2003)
Gastroenterology
, vol.125
, Issue.6
, pp. 1714-1722
-
-
Lok, A.S.1
Lai, C.L.2
Leung, N.3
-
47
-
-
33845671388
-
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
-
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (6), 1743-1751 (2006).
-
(2006)
Gastroenterology
, vol.131
, Issue.6
, pp. 1743-1751
-
-
Hadziyannis, S.J.1
Tassopoulos, N.C.2
Heathcote, E.J.3
-
48
-
-
4344627233
-
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine
-
Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 48 (9), 3498-3507 (2004).
-
(2004)
Antimicrob. Agents Chemother
, vol.48
, Issue.9
, pp. 3498-3507
-
-
Tenney, D.J.1
Levine, S.M.2
Rose, R.E.3
-
49
-
-
43049174567
-
Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response
-
Baldick CJ, Eggers BJ, Fang J et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J. Hepatol. 48 (6), 895-902 (2008).
-
(2008)
J. Hepatol
, vol.48
, Issue.6
, pp. 895-902
-
-
Baldick, C.J.1
Eggers, B.J.2
Fang, J.3
-
50
-
-
33644882231
-
Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype
-
Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am. J. Gastroenterol. 101 (2), 297-303 (2006).
-
(2006)
Am. J. Gastroenterol
, vol.101
, Issue.2
, pp. 297-303
-
-
Flink, H.J.1
van Zonneveld, M.2
Hansen, B.E.3
de Man, R.A.4
Schalm, S.W.5
Janssen, H.L.6
-
51
-
-
21244447705
-
Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
-
Lau GK, Piratvisuth T, Luo KX et al. Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352 (26), 2682-2695 (2005).
-
(2005)
N. Engl. J. Med
, vol.352
, Issue.26
, pp. 2682-2695
-
-
Lau, G.K.1
Piratvisuth, T.2
Luo, K.X.3
-
52
-
-
19944428132
-
Pegylated interferon a-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial
-
Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon a-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (9454), 123-129 (2005).
-
(2005)
Lancet
, vol.365
, Issue.9454
, pp. 123-129
-
-
Janssen, H.L.1
van Zonneveld, M.2
Senturk, H.3
-
53
-
-
33644539558
-
Therapy of hepatitis B - viral suppression or eradication?
-
Perrillo R P. Therapy of hepatitis B - viral suppression or eradication? Hepatology 43 (2, Suppl. 1), S182-S193 (2006).
-
(2006)
Hepatology
, vol.43
, Issue.2 and SUPPL. 1
-
-
Perrillo, R.P.1
-
54
-
-
39549114267
-
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon a-2a for HBeAg-positive chronic hepatitis B
-
Fried MW, Piratvisuth T, Lau GK et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon a-2a for HBeAg-positive chronic hepatitis B. Hepatology 47 (2), 428-434 (2008).
-
(2008)
Hepatology
, vol.47
, Issue.2
, pp. 428-434
-
-
Fried, M.W.1
Piratvisuth, T.2
Lau, G.K.3
-
55
-
-
34247538953
-
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
-
Bonino F, Marcellin P, Lau GK et al. Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56 (5), 699-705 (2007).
-
(2007)
Gut
, vol.56
, Issue.5
, pp. 699-705
-
-
Bonino, F.1
Marcellin, P.2
Lau, G.K.3
-
56
-
-
5044229895
-
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance
-
Andreone P, Gramenzi A, Cursaro C et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J. Viral Hepat. 11 (5), 439-442 (2004).
-
(2004)
J. Viral Hepat
, vol.11
, Issue.5
, pp. 439-442
-
-
Andreone, P.1
Gramenzi, A.2
Cursaro, C.3
-
57
-
-
34547148385
-
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B
-
Keeffe EB, Zeuzem S, Koff RS et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 5 (8), 890-897 (2007).
-
(2007)
Clin. Gastroenterol. Hepatol
, vol.5
, Issue.8
, pp. 890-897
-
-
Keeffe, E.B.1
Zeuzem, S.2
Koff, R.S.3
|